These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31563157)

  • 21. [Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy].
    Amato L; Minozzi S; Mitrova Z; Parmelli E; Saulle R; Cruciani F; Vecchi S; Davoli M
    Epidemiol Prev; 2017; 41(5-6):279-293. PubMed ID: 29119763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cannabis--Position Paper of the German Respiratory Society (DGP)].
    Kreuter M; Nowak D; Rüther T; Hoch E; Thomasius R; Vogelberg C; Brockstedt M; Hellmann A; Gohlke H; Jany B; Loddenkemper R
    Pneumologie; 2016 Feb; 70(2):87-97. PubMed ID: 26935046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors.
    Lucas P; Walsh Z; Crosby K; Callaway R; Belle-Isle L; Kay R; Capler R; Holtzman S
    Drug Alcohol Rev; 2016 May; 35(3):326-33. PubMed ID: 26364922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS).
    Ware MA; Wang T; Shapiro S; Collet JP;
    J Pain; 2015 Dec; 16(12):1233-1242. PubMed ID: 26385201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term medical cannabis use and risk factors for diversion: Report on physician's guidance and patients' behaviour.
    Sznitman SR; Goldberg V; Sheinman-Yuffe H; Zolotov Y; Flechter E; Bar-Sela G
    Palliat Support Care; 2020 Feb; 18(1):18-23. PubMed ID: 31190678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cannabis use predicts risks of heart failure and cerebrovascular accidents: results from the National Inpatient Sample.
    Kalla A; Krishnamoorthy PM; Gopalakrishnan A; Figueredo VM
    J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):480-484. PubMed ID: 29879084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabis, a potential treatment option in pediatric IBD? Still a long way to go.
    Halbmeijer N; Groeneweg M; De Ridder L
    Expert Rev Clin Pharmacol; 2019 Apr; 12(4):355-361. PubMed ID: 30767696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use.
    Walsh Z; Callaway R; Belle-Isle L; Capler R; Kay R; Lucas P; Holtzman S
    Int J Drug Policy; 2013 Nov; 24(6):511-6. PubMed ID: 24095000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical cannabis: Risks related to its indication prior to approval.
    Appiani FJ; Duarte JM
    Arch Argent Pediatr; 2020 Feb; 118(1):64-67. PubMed ID: 31984702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical cannabis use in older patients: Update on medical knowledge.
    Beauchet O
    Maturitas; 2018 Dec; 118():56-59. PubMed ID: 30415756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medical cannabis: What practitioners need to know.
    Van Rensburg R; Pillay-Fuentes Lorente V; Blockman M; Moodley K; Wilmshurst JM; Decloedt EH
    S Afr Med J; 2020 Feb; 110(3):192-196. PubMed ID: 32657695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases.
    Fitzcharles MA; Niaki OZ; Hauser W; Hazlewood G;
    J Rheumatol; 2019 May; 46(5):532-538. PubMed ID: 30647183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can cannabis be considered a substitute medication for alcohol?
    Subbaraman MS
    Alcohol Alcohol; 2014; 49(3):292-8. PubMed ID: 24402247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users.
    Turna J; Simpson W; Patterson B; Lucas P; Van Ameringen M
    J Psychiatr Res; 2019 Apr; 111():134-139. PubMed ID: 30738930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….
    Baron EP
    Headache; 2015 Jun; 55(6):885-916. PubMed ID: 26015168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabis and Neuropsychiatry, 2: The Longitudinal Risk of Psychosis as an Adverse Outcome.
    Andrade C
    J Clin Psychiatry; 2016 Jun; 77(6):e739-42. PubMed ID: 27337422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Changing Drug Culture: Medical and Recreational Marijuana.
    Albertson TE; Chenoweth JA; Colby DK; Sutter ME
    FP Essent; 2016 Feb; 441():11-7. PubMed ID: 26881768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use?
    Hall W
    Addiction; 2015 Jan; 110(1):19-35. PubMed ID: 25287883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical Marijuana programs: implications for cannabis control policy--observations from Canada.
    Fischer B; Kuganesan S; Room R
    Int J Drug Policy; 2015 Jan; 26(1):15-9. PubMed ID: 25287942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.